Acumen Pharmaceuticals, Inc. (ABOS) 10-Year Financial Performance & Capital Metrics

ABOS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Show more

Revenue $0
EBITDA -$114M -86.8%
Net Income -$102M -95.4%
EPS (Diluted) -1.71 -58.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -45.6% -98.4%
ROIC -42.28% -32.5%
Debt/Equity 0.16 +53.1%
Interest Coverage -28.03 +73.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 23.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-62.04%

ROCE

10Y Avg-45.53%

5Y Avg-28.53%

3Y Avg-30.62%

Latest-44.84%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.7M	1.44M	0	0	0	0
Revenue Growth %	-	-0.15%	-1%	-	-	-
Cost of Goods Sold+	8.58M	8M	12.3M	0	0	0
COGS % of Revenue	5.05%	5.57%	-	-	-	-
Gross Profit+	-6.88M	-6.56M	-12.3M	0	0	0
Gross Margin %	-4.05%	-4.57%	-	-	-	-
Gross Profit Growth %	-	0.05%	-0.88%	1%	-	-
Operating Expenses+	926K	1.35M	7.28M	45.24M	61.14M	114.02M
OpEx % of Revenue	0.55%	0.94%	-	-	-	-
Selling, General & Admin	926K	1.35M	7.28M	12.88M	18.82M	20.22M
SG&A % of Revenue	0.55%	0.94%	-	-	-	-
Research & Development	8.58M	8M	12.3M	32.36M	42.32M	93.8M
R&D % of Revenue	5.05%	5.57%	-	-	-	-
Other Operating Expenses	-8.58M	-8M	-12.3M	0	0	0
Operating Income+	-7.8M	-7.91M	-19.58M	-45.24M	-61.14M	-114.02M
Operating Margin %	-4.6%	-5.51%	-	-	-	-
Operating Income Growth %	-	-0.01%	-1.48%	-1.31%	-0.35%	-0.86%
EBITDA+	0	-7.91M	-19.58M	-45.07M	-60.95M	-113.84M
EBITDA Margin %	-	-5.51%	-	-	-	-
EBITDA Growth %	-	-	-1.47%	-1.3%	-0.35%	-0.87%
D&A (Non-Cash Add-back)	7.8M	0	4K	169K	184K	178K
EBIT	-7.8M	-7.91M	-19.58M	-42.86M	-51.79M	-98.26M
Net Interest Income+	45K	1K	84K	2.39M	10.21M	10.25M
Interest Income	45K	1K	84K	2.39M	10.79M	14.32M
Interest Expense	0	0	0	0	581K	4.07M
Other Income/Expense	-102K	587K	-81.02M	2.38M	8.77M	11.69M
Pretax Income+	-7.91M	-7.33M	-100.61M	-42.86M	-52.37M	-102.33M
Pretax Margin %	-4.66%	-5.1%	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-7.91M	-7.33M	-100.61M	-42.86M	-52.37M	-102.33M
Net Margin %	-4.66%	-5.1%	-	-	-	-
Net Income Growth %	-	0.07%	-12.73%	0.57%	-0.22%	-0.95%
Net Income (Continuing)	-7.91M	-7.33M	-100.61M	-42.86M	-52.37M	-102.33M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.27	-0.26	-2.63	-1.06	-1.08	-1.71
EPS Growth %	-	0.04%	-9.12%	0.6%	-0.02%	-0.58%
EPS (Basic)	-0.20	-0.26	-2.63	-1.06	-1.08	-1.71
Diluted Shares Outstanding	28.65M	28.65M	38.27M	40.6M	48.61M	60.01M
Basic Shares Outstanding	28.65M	28.65M	38.27M	40.6M	48.49M	60.01M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.18M	44.43M	198.66M	180.33M	246.62M	178.31M
Cash & Short-Term Investments	6.55M	43.78M	194.24M	177.6M	243.52M	171.56M
Cash Only	6.55M	43.78M	122.16M	130.1M	66.89M	35.63M
Short-Term Investments	0	0	72.08M	47.5M	176.64M	135.93M
Accounts Receivable	30K	109K	0	0	225K	0
Days Sales Outstanding	6.45	27.71	-	-	-	-
Inventory	0	0	0	199K	0	159K
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	7K	447K	2.83M	1.42M	1.96M	5.73M
Total Non-Current Assets+	144K	0	31.67M	16.26M	63.51M	60.69M
Property, Plant & Equipment	0	0	36K	270K	503K	339K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	169K	0
Long-Term Investments	0	0	31.62M	15.84M	62.55M	59.97M
Other Non-Current Assets	144K	0	14K	151K	285K	379K
Total Assets+	7.32M	44.43M	230.33M	196.59M	310.13M	238.99M
Asset Turnover	0.23x	0.03x	-	-	-	-
Asset Growth %	-	5.07%	4.18%	-0.15%	0.58%	-0.23%
Total Current Liabilities+	1.34M	6.37M	5.15M	7.81M	12.97M	27.61M
Accounts Payable	223K	531K	1.09M	1.64M	1.38M	5.65M
Days Payables Outstanding	9.49	24.24	32.27	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	614K	5.5M	2.96M	131K	3.9M	230K
Current Ratio	5.35x	6.98x	38.60x	23.08x	19.01x	6.46x
Quick Ratio	5.35x	6.98x	38.60x	23.06x	19.01x	6.45x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	17.4M	56.65M	0	0	30.18M	29.57M
Long-Term Debt	0	0	0	0	27.34M	29.42M
Capital Lease Obligations	0	0	0	0	284K	150K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	17.4M	56.65M	0	0	2.56M	0
Total Liabilities	18.74M	63.02M	5.15M	7.81M	43.15M	57.18M
Total Debt+	0	0	0	105K	28.49M	29.7M
Net Debt	-6.55M	-43.78M	-122.16M	-130M	-38.4M	-5.92M
Debt / Equity	-	-	-	0.00x	0.11x	0.16x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-105.23x	-28.03x
Total Equity+	-11.42M	-18.59M	225.18M	188.78M	266.97M	181.82M
Equity Growth %	-	-0.63%	13.11%	-0.16%	0.41%	-0.32%
Book Value per Share	-0.40	-0.65	5.88	4.65	5.49	3.03
Total Shareholders' Equity	-11.42M	-18.59M	225.18M	188.78M	266.97M	181.82M
Common Stock	0	0	4K	4K	6K	6K
Retained Earnings	-19.64M	-26.96M	-127.57M	-170.43M	-222.8M	-325.13M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-231K	-751K	312K	-48K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.82M	-7.45M	-17.96M	-35.15M	-43.06M	-86.22M
Operating CF Margin %	-4.02%	-5.19%	-	-	-	-
Operating CF Growth %	-	-0.09%	-1.41%	-0.96%	-0.23%	-1%
Net Income	-7.91M	-7.33M	-100.61M	-42.86M	-52.37M	-102.33M
Depreciation & Amortization	0	0	4K	169K	184K	178K
Stock-Based Compensation	174K	154K	922K	3.06M	6.14M	9.63M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	147K	-586K	81.42M	487K	-888K	-5.35M
Working Capital Changes	768K	307K	298K	3.99M	3.87M	11.65M
Change in Receivables	200K	-79K	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	110K	308K	557K	552K	-261K	4.27M
Cash from Investing+	0	0	-104.12M	39.19M	-171.67M	48.03M
Capital Expenditures	0	0	-40K	-161K	-21K	-16K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	39.35K	0	0
Cash from Financing+	6.24M	44.67M	200.47M	3.91M	151.75M	6.93M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	7K	0	1.88M	115K	-151K	-230K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-6.82M	-7.45M	-18M	-35.31M	-43.09M	-86.23M
FCF Margin %	-4.02%	-5.19%	-	-	-	-
FCF Growth %	-	-0.09%	-1.42%	-0.96%	-0.22%	-1%
FCF per Share	-0.24	-0.26	-0.47	-0.87	-0.89	-1.44
FCF Conversion (FCF/Net Income)	0.86x	1.02x	0.18x	0.82x	0.82x	0.84x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-97.4%	-20.71%	-22.98%	-45.6%
Return on Invested Capital (ROIC)	-	-	-72.26%	-41.94%	-31.91%	-42.28%
Gross Margin	-405.36%	-456.89%	-	-	-	-
Net Margin	-465.94%	-510.1%	-	-	-	-
Debt / Equity	-	-	-	0.00x	0.11x	0.16x
Interest Coverage	-	-	-	-	-105.23x	-28.03x
FCF Conversion	0.86x	1.02x	0.18x	0.82x	0.82x	0.84x
Revenue Growth	-	-15.38%	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Acumen Pharmaceuticals, Inc. (ABOS) grew revenue by 0.0% over the past year. Growth has been modest.

Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $133.4M for fiscal year 2024.

Dividend & Returns

Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity (ROE) of -45.6%. Negative ROE indicates the company is unprofitable.

Acumen Pharmaceuticals, Inc. (ABOS) had negative free cash flow of $123.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener